Skip to main content

Market Overview

Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue

Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue
  • Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.89 per share for the first quarter, beating the $9.03 estimate. Revenue of $2.53 billion narrowly missed analyst consensus of $2.56 billion.
  • Total revenues increased 38% Y/Y to $2.53 billion, boosted by a strong rebound in Regeneron’s Eylea eye disease drug and the contribution from its COVID-19 antibody cocktail treatment, REGEN-COV. Revenues excluding REGEN-COV increased by 20% Y/Y to $2.2 billion.
  • Q1 Eylea U.S. net sales increased 15% Y/Y to $1.35 billion. Total revenues also include collaboration revenues of $754 million, up 43% Y/Y.
  • Sanofi SA’s (NASDAQ: SNY) collaboration revenue increased primarily due to the company’s share of profits from the commercialization of antibodies at $261 million compared to $171 million in Q1 of 2020.
  • Higher Dupixent profits primarily drove the change in Regeneron’s profit share from the commercialization of antibodies.
  • Operating margin improved to 64.5% from 56.6% a year ago. Regeneron generated a free cash flow of $553.2 million.
  • Guidance: For 2021, the company sees an adjusted gross margin of 87%–89%. It expects Capex of $585 - $650 million lower than the previous guidance of $600–$680 million. It did not provide full-year EPS or sales guidance.
  • Price Action: REGN shares are up 0.6% at $485.42 in the premarket session on the last check Thursday.

Related Articles (REGN)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech Earnings News Guidance Health Care General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at